[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-screening":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,49,73,102,125,171,195,220,242,268,292,320,347,370,396,427,458,484,510,543,572,595,617,637,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100615711","my-self-sampling-for-hpv-awareness-results-and-empowerment-100615711",false,"NCT07296159","My Self-Sampling for HPV Awareness, Results, and Empowerment","A Technology-enhanced and Multilevel Approach to Promote Cervical Cancer Prevention Among Women Living With HIV","MySHARE+","Aim 1 Provider Prompt: Healthcare and\u002For service provider to women living with HIV\n\nAim 2 RCT Pilot\n\nInclusion Criteria:\n\n* Have an HIV diagnosis\n* Are between 30 to 65 years old\n* Have not had a Pap smear within the last 12 months or more.\n\nExclusion Criteria:\n\n* Have had a history of hysterectomy or invasive cervical cancer\n* Are currently pregnant or were pregnant in the past 3 months\n* Are currently participating or enrolled in similar studies within the past year.",true,"ALL","30 Years","65 Years",{"count":23,"type":24},130,"ESTIMATED","INTERVENTIONAL",[27],"NA","The overall objective of this study is to conduct formative research and pilot test the provider-level and patient-level components of the My Self-Sampling for HPV Awareness, Results, and Empowerment (MySHARE+) intervention. MySHARE+ aims to harness the power of technology and apply a multilevel approach to promote the adoption of cervical cancer screening (HPV self-sampling; Pap triage adherence) among under\u002Fnever-screened women living with HIV (WLH). The specific aims are to 1) identify facilitators and barriers to implementing a healthcare provider prompt in a primary care setting and 2) conduct a pilot randomized controlled trial (RCT) to examine the feasibility, acceptability, and preliminary efficacy of a mHealth educational intervention in promoting cervical cancer awareness and HPV self-sampling among WLH.\n\nUnder aim 1: Providers of healthcare and\u002For social services to WLH will complete an online survey to identify barriers to implementing a healthcare provider prompt in a primary care setting and participate in semi-structured interviews to provide feedback on drafted prompts. Prompts will be piloted at one local clinic to improve patient-provider communication about cervical cancer screening, followed with semi-structured interviews with providers involved.\n\nUnder aim 2: Participants will be enrolled in a text messaging intervention and sent an HPV self-sampling test kit to return via mail. Participants in the intervention group will receive the full mHealth intervention while the control group will receive more generic text messages and reminders over the course of the study.",[30,31,32],"Cervical Cancer","Cervical Cancer Screening","HPV",[34,32,35,36],"Cervical cancer","HPV self-sampling","mHealth","NOT_YET_RECRUITING","2026-08-14",{"date":40,"type":41},"2026-08-18","ACTUAL",{"date":43,"type":24},"2027-01-01",{"date":45,"type":24},"2029-08-31",{"name":47,"class":48},"Daisy Le","OTHER",{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":18,"sex":56,"minAge":20,"maxAge":21,"enrollmentInfo":57,"targetDuration":4,"studyType":25,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100641565","developing-and-implementing-hpv-screened-100641565","NCT07657104","Developing and Implementing HPV SCREENED","Developing and Implementing HPV SCREENED (Self-Collection REach and ENgagement in Emergency Departments) to Improve Cancer Equity","Inclusion Criteria:\n\n* biological women,\n* no prior hysterectomy or cervical cancer,\n* not pregnant,\n* last Pap \\>3 years, last co-test \\>5 years, or last HPV alone test \\>5 years,\n* speak English or Spanish,\n* has a working cellphone,\n* NJ residency\n* ED patient\n\nExclusion Criteria:\n\n* currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy);\n* previous hysterectomy;\n* previous diagnosis of cervical cancer;\n* current menses","FEMALE",{"count":58,"type":24},100,[27],"This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.",[31,62],"Human Papilloma Virus","2026-08-10",{"date":65,"type":41},"2026-08-11",{"date":67,"type":24},"2026-08-20",{"date":69,"type":24},"2027-09-30",{"name":71,"class":48},"Rutgers, The State University of New Jersey",2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":56,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":25,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100583132","personalized-risk-based-follow-up-of-cervical-cancer-screening-in-practice-rct-100583132","NCT06872346","Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT","Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice (PREDICT), Randomized Control Trial","PREDICT","Inclusion Criteria, Individuals who:\n\n* have a cervix and are 21-70 years old\n* receive care at a participating primary care practice (i.e. PCP team visit within past 3 years)\n* have had a Pap and\u002F or HPV test within the past 3.5 years\n* has a CCSM result that suggest a 5-year risk of developing CIN3+ that warrants surveillance at 1 or 3 years, diagnostic colposcopy, or treatment (i.e., above average risk).\n\nInclusion of those up to age 70 is intended to identify individuals whose prior history does not meet screening exit criteria, and warrants surveillance or diagnostic care even though women with adequate prior screening can stop at age 65\n\nExclusion Criteria Individuals who:\n\n* were diagnosed with cervical cancer\u002F CIN3+ prior to the most recent screening Pap or HPV test\n* have had their cervix removed\n* are not English or Spanish-speaking.","21 Years","70 Years",{"count":84,"type":24},7500,[27],"The goal of this PREDICT is to assess a personalize approach to screening and management of cervical cancer testing. The investigators will evaluate patients who are due for a follow up cervical cancer screening in the primary care clinics in the Massachusetts General Brigham system. Patients will be randomized by clinic into three different arms (Arm 1: standard care, Arm 2: visit based reminders, Arm 3: visit based reminders and population health outreach)",[31],[30,89,90],"Screening","Clinical Decision Support","RECRUITING","2026-08-05",{"date":94,"type":41},"2026-08-07",{"date":96,"type":41},"2026-07-22",{"date":98,"type":24},"2029-01-22",{"name":100,"class":48},"Massachusetts General Hospital",1,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":18,"sex":56,"minAge":20,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":25,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":101},"100634312","single-visit-clinical-validation-of-screenfire-a-low-cost-hpv-test-efficacy-and-cost-effectiveness-phase-2-100634312","NCT07538050","Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)","Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)","SCALE AIM 2","Inclusion Criteria:\n\n* Women between 30-59 years of age\n* Willing to conduct HPV self-sampling\n\nExclusion Criteria:\n\n* Prior hysterectomy\n* HPV testing in at least 5 years\n* Previous diagnosis or treatment of invasive cancer","59 Years",{"count":112,"type":24},1000,[27],"In high-income countries, prevention strategies have led to declines in cervical cancer rates by more than 75% in high-income countries. In contrast, low- and middle-income countries (LMICs) carry the global burden of cervical cancer with about 85% of new cases and 90% mortality. Screening is an essential component of effective prevention to reduce this disease burden. The World Health Organization recommends human papillomavirus (HPV) testing as the most effective screening method. However, HPV testing can be expensive and complex to implement. Most tests require central laboratory processing, which means women must come back for a different visit to obtain results and potential treatment. In LMICs, this often results in high loss to follow up because many women face transportation and other challenges. The development of new, low-cost HPV tests that can be processed locally as the potential to improve adherence in screening programs. In this study, the research team will assess the feasibility of a same-day screen-and-treat approach compared to the standard two-visit regime in the context of the cervical cancer prevention program in El Salvador. This will be a cross-sectional study that will enroll 1,000 women in remote areas of the country over 10-15 weeks. The hypothesis is that at least 10% fewer women lost to follow-up at six months using the single visit approach compared to the \\>20% historical loss to follow-up using the standard two-visit approach.",[31],"2026-07-31",{"date":118,"type":41},"2026-08-03",{"date":120,"type":41},"2026-04-16",{"date":122,"type":24},"2027-12-31",{"name":124,"class":48},"The Cleveland Clinic",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":18,"sex":56,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":25,"phases":135,"briefSummary":136,"conditions":137,"keywords":147,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":170},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592","NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.","25 Years",{"count":134,"type":24},450,[27],"The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[138,139,140,31,141,142,32,143,144,145,146],"HPV Infection","HPV 16 Infection","High Risk HPV","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV (Human Papillomavirus)-Associated","HPV DNA","HPV Infections","Screening Test",[148,149,150,151,152,153,154,155,156,157,32,158,159,160],"Q-Pad","Self-sampling","Self-collection","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection",{"date":162,"type":41},"2026-07-24",{"date":164,"type":41},"2025-12-01",{"date":166,"type":24},"2027-03",{"name":168,"class":169},"Qurasense","INDUSTRY",3,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":56,"minAge":20,"maxAge":21,"enrollmentInfo":178,"targetDuration":4,"studyType":25,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":101},"100446329","st-josephs-hpv-self-sampling-offering-a-self-sampling-option-in-clinic-100446329","NCT05092022","St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic","Increasing Cancer Screening Among Female Patients at PSH St. Joseph's Residency Clinic: Offering a Self-sampling Option in Clinic","Inclusion Criteria:\n\n* Eligible but out-of-date for cervical cancer screening\n* Able to speak, read, and communicate well in English or Spanish\n* Not at greater than average risk for cervical cancer\n\nExclusion Criteria:\n\n* Pregnant\n* Incarcerated\n* Greater than average risk for cervical cancer, for example:\n\n  * Already diagnosed with high-grade precancerous cervical cancer or cervical lesions\n  * Has a compromised immune system\n* Unable to speak, read, and communicate well in English or Spanish\n* Unable or unwilling to give implied consent or otherwise complete study requirements",{"count":179,"type":24},50,[27],"This study aims to evaluate the effectiveness of offering self-sampled human papillomavirus (HPV) tests in increasing participation in cervical cancer screening, compared to the standard of care clinician-sampled test. The primary study endpoints are (1) patients' acceptability of self-sampled HPV tests vs. clinician-sampled test, and (2) patients' completion of self-sampled HPV test. The secondary study endpoint to be measured is the increase in cervical cancer screenings of any type in the PSH St. Joseph's residency clinic patient population.",[31],[184,185],"self-sampling","cervical cancer","2026-07-01",{"date":188,"type":41},"2026-07-06",{"date":190,"type":41},"2023-09-18",{"date":192,"type":24},"2026-12-31",{"name":194,"class":48},"Milton S. Hershey Medical Center",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":19,"minAge":132,"maxAge":21,"enrollmentInfo":203,"targetDuration":4,"studyType":25,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":101},"100577620","home-based-self-sampling-for-cervical-cancer-prevention-education-intervention-in-ghana-100577620","NCT06800664","Home-based Self-sampling for Cervical Cancer Prevention Education Intervention in Ghana","The Impact of an Evidence-Based, Behavioral Cervical Cancer Screening Intervention Among Women Living With HIV in Ghana (HOPE-inG): A Type 2 Hybrid Effectiveness Implementation Trial","HOPE-inG","Inclusion Criteria:\n\nGeneral criteria\n\n* ability to give consent per Institutional Review Board stipulations\n* residing in the Central Region\n* having no medical characteristics that would interfere with the ability to participate fully\n* the willingness to participate in this study.\n\n  (a) Healthcare provider eligibility: Inclusion criteria include an individual (no gender restrictions) who\n* possesses healthcare qualifications (i.e., patient navigators, physicians, nurses, health facility management),\n* works at the HIV health facility at study sites,\n* is ≥18 years old. (b) Eligibility for women living with HIV (Patients)\n* identified female at birth) who\n* are living with HIV between 25 and 65 years old (age consistent with WHO CC screening guidelines)\n* have never had CC screening (Pap or HPV test),\n* have not had a screening for the past 5 years\n\nExclusion Criteria:\n\n* Women will be excluded if they are pregnant or have had a hysterectomy.\n* WLWH who have a cervix are the main target population to develop the HOPE toolkit.\n* Women who are below 25 and those who are above 65 years will be excluded.",{"count":204,"type":24},1500,[27],"The investigators propose to develop and\u002For adapt implementation strategies and a structured implementation plan to translate the HOPE intervention into existing healthcare practice in Ghana.\n\nThese \"implementation support strategies (ISS)\" are implementation strategies relevant to implementation support, which is concerned with moving (implementation) research into (implementation) practice.\n\nThe ultimate goal is to facilitate health system adoption and sustainment.",[31,208,149,209,210,211],"HIV","Implementation Science","Intervention (Training) Condition","Implementation Strategies","2026-06-30",{"date":186,"type":41},{"date":215,"type":41},"2025-11-11",{"date":217,"type":24},"2029-05",{"name":219,"class":48},"Baylor University",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":18,"sex":56,"minAge":132,"maxAge":21,"enrollmentInfo":228,"targetDuration":4,"studyType":25,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":101},"100640548","a-mobile-web-app-intervention-to-promote-cervical-cancer-screening-100640548","NCT07574190","A Mobile Web App Intervention to Promote Cervical Cancer Screening","A Mobile Web App Intervention to Promote Cervical Cancer Screening Among Indigenous Women","wPap","Inclusion Criteria:\n\n* Women who are self-identified AI women of the YST in SD\n* Women who are aged 25 to 65 years\n* Women who have not received any of the following cervical cancer screening tests: a Pap test within the past 3 years, primary HPV testing within the past 5 years, or HPV\u002FPap co-testing within the past 5 years.\n* Women who are willing to use their own mobile phone, iPad, tablets, and computers, or a mobile phone borrowed from the research team for the wPap intervention.\n\nExclusion Criteria:\n\n* Women younger than 25 years or older than 65 years\n* Women who are currently up to date with cervical cancer screening according to recommended guidelines (Pap test within the past 3 years, primary HPV testing within the past 5 years, or HPV\u002FPap co-testing within the past 5 years)\n* Women with a prior diagnosis of cervical cancer\n* Women who have had a total hysterectomy that included removal of the cervix, without a history of high-grade precancerous lesions\n* Women with a previous colposcopy examination indicating abnormal cytology that requires more frequent screening than every 3 years",{"count":229,"type":24},120,[27],"The overarching goal of this study is to increase cervical cancer (CC) screening rates among Indigenous women in the U.S. Specifically, the study aims to develop and evaluate a culturally tailored, multilevel, multimedia mobile web app intervention (wPap) for women of the Yankton Sioux Tribe (YST) living on the YST Reservation in South Dakota.\n\nThe wPap intervention will be tested in a randomized clinical trial (RCT) involving 120 YST women aged 25-65. Participants will be randomly assigned to either: (a) the wPap intervention group (n = 60), receiving personalized, culturally tailored multilevel multimedia messages through a mobile web app along with health navigator support, or (b) a waitlist control group (n = 60), receiving printed educational materials on cervical cancer and screening guidelines along with health navigator support. The intervention will last seven days, with assessments conducted at baseline, one week post-intervention, and six months post-intervention via surveys and telephone follow-up.\n\nThe study tests the following hypotheses:\n\n(H1) women in the wPap intervention group will achieve higher CC screening rates than the waitlist control group; (H2) the wPap group will demonstrate greater improvements in knowledge, attitudes\u002Fbeliefs, self-efficacy, and intention to undergo CC screening; and (H3) the wPap group will report higher satisfaction and acceptance of the intervention compared with the waitlist control group. Findings will inform the feasibility, acceptability, and efficacy of mobile web app interventions tailored to Indigenous communities to improve CC screening.",[31],"2026-05-19",{"date":235,"type":41},"2026-05-22",{"date":237,"type":24},"2026-05",{"date":239,"type":24},"2026-11-15",{"name":241,"class":48},"University of South Dakota",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":18,"sex":56,"minAge":20,"maxAge":21,"enrollmentInfo":249,"targetDuration":4,"studyType":25,"phases":251,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":101},"100619536","emergency-department-based-cervical-cancer-screening-through-self-sampling-100619536","NCT07345897","Emergency Department-based Cervical Cancer Screening Through Self-sampling","Advancing Cervical Cancer Screening Through Emergency Department-based Self-Sampling","Inclusion Criteria:\n\n* Cisgender women and transgender\u002Fnon-binary individuals with a cervix,\n* Age 30 - 65 years, and demonstrating decisional capacity to consent to participate with no known exclusion criteria present.\n\nExclusion Criteria:\n\n* Past hysterectomy with cervical removal\n* Known infection with HIV (as screening recommendations for people with HIV differ from the general population)\n* Inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)\n* Current pregnancy or in the three months after giving birth\n* Use of vaginal ovules, creams or washes, vaginal contraceptives or condoms within past 3 days\n* Sexual intercourse or transvaginal ultrasound scans or gynecological examinations within past 2 days",{"count":250,"type":24},200,[27],"This project will compare the uptake of cervical cancer screening through ED HPV sampling among patients presenting to the ED.",[32,254,255,31,142],"HPV Associated Cancers","HPV Cancers",[257,258,32,34],"HPV Screening","Cervical cancer screening","2026-04-27",{"date":261,"type":41},"2026-05-04",{"date":263,"type":41},"2026-02-13",{"date":265,"type":24},"2028-01",{"name":267,"class":48},"University of Rochester",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":56,"minAge":275,"maxAge":4,"enrollmentInfo":276,"targetDuration":278,"studyType":279,"phases":4,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":4},"100634887","hpv-testing-as-a-prevention-of-cervical-dysplasia-and-cancer-before-planned-subtotal-hysterectomy-100634887","NCT07545525","HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy","HPV Testing as a Prevention of Cervical Dysplasia and Cervical Cancer Before Planned Subtotal Hysterectomy","Inclusion Criteria:\n\n* age over 18\n* indication for subtotal hysterectomy\n* consent to provide conisation in case the HPV test result is positive\n\nExclusion Criteria:\n\n* negative HPV test in the last 3 years","18 Years",{"count":277,"type":24},300,"6 Months","OBSERVATIONAL","Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy",[31,282],"Human Papilloma Virus (HPV)","2026-04-21",{"date":285,"type":41},"2026-04-22",{"date":287,"type":24},"2026-04",{"date":289,"type":24},"2029-04",{"name":291,"class":48},"General University Hospital, Prague",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":19,"minAge":275,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":25,"phases":301,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100634547","cancer-awareness-among-syrian-migrants-100634547","NCT07541105","Cancer Awareness Among Syrian Migrants","A Theory-Driven Educational Intervention to Enhance Cancer Screening Uptake Among Syrian Migrants in Turkey: A Study Protocol","Inclusion Criteria:\n\n* over 18 years of age\n* hold Syrian citizenship\n* be registered with the Migrant Health Center in Mersin province\n* have proficiency in Turkish or Arabic\n* voluntarily agree to participate\n\nExclusion Criteria:\n\n* if they hold Turkish citizenship\n* have a diagnosed psychiatric disorder\n* have been diagnosed with cancer\n* wish to withdraw from the study",{"count":300,"type":24},30,[27],"This study aims to develop and evaluate a theory-based educational intervention to improve cancer screening participation among Syrian migrants in Turkey. The study will also develop a Cancer Protection Motivation Scale (CPMS) to measure individuals' motivation toward cancer screening. Using a mixed-methods design, the study will explore barriers, beliefs, and behaviors related to breast, cervical, and colorectal cancer screening. The effectiveness of the intervention will be assessed using a pretest-posttest design. The findings are expected to support culturally appropriate strategies to improve cancer screening uptake among migrant populations.",[304,31,305,306],"Breast Cancer Screening","Colorectal Cancer Screening","Cancer Prevention Behavior",[308,309,34,310,311],"Breast cancer","Colon cancer","Protection motivation","Reduced inequalities","2026-04-20",{"date":314,"type":41},"2026-04-24",{"date":312,"type":24},{"date":317,"type":24},"2026-07-15",{"name":319,"class":48},"Toros University",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":18,"sex":56,"minAge":20,"maxAge":21,"enrollmentInfo":328,"targetDuration":4,"studyType":25,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":101},"100461238","using-artificial-intelligence-based-chatbot-to-improve-womens-participation-to-cervical-cancer-screening-programme-100461238","NCT05286034","Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme","Artificial Intelligence-assisted Decision-making to Improve Women's Participation to Cervical Cancer Screening in Occitanie Region-France","AppDate-You","Inclusion criteria: eligible women will be:\n\n* aged 30-65\n* did not perform a pap smear in the last 4 years\n* are living in deprived clusters in the Occitanie region.\n* did not answer to a first \"invitation\" letter to perform a clinician-collected HPV testing\n\nExclusion criteria: ineligible women will be those:\n\n* outside the target age group\n* had a Pap smear in the past 3 years\n* had hysterectomy including cervix\n* are pregnant\n* already scheduled a screening appointment or had just attended a HPV screening\n* had a cervical abnormality that was under exploration and\u002For treatment.\n* participated to the study pilot",{"count":329,"type":24},3000,[27],"This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive.",[31,30],[334,152,335,336,337,338],"cervical neoplasia","chatbot","artificial intelligence","cluster randomized controlled trial","HPV vaginal self-sampling","2026-03-25",{"date":341,"type":41},"2026-03-27",{"date":343,"type":41},"2025-11-03",{"date":40,"type":24},{"name":346,"class":48},"International Agency for Research on Cancer",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":18,"sex":56,"minAge":353,"maxAge":21,"enrollmentInfo":354,"targetDuration":278,"studyType":279,"phases":4,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":101},"100628971","community-implementation-of-urine-hpv-test-and-reflex-dna-methylation-test-in-cervical-cancer-screening-100628971","NCT07468578","Community Implementation of Urine HPV Test and Reflex DNA Methylation Test in Cervical Cancer Screening","Inclusion Criteria:\n\n* Women aged 26-65\n* History of sexual activity\n\nExclusion Criteria:\n\n* Pregnancy\n* History of total hysterectomy\n* History of cervical cancer\n* Currently under treatment for cervical dysplasia or cervical cancer\n* Unwilling to participate in the study\n* Cannot give written consent to the procedure","26 Years",{"count":355,"type":24},8620,"Aims:\n\nThe project aims to explore the acceptability and feasibility of a self-sampling, urine-based HPV test (INDICAID HPV Urine Test) in a community setting, and the effectiveness of DNA methylation test for triaging high-risk HPV (HR-HPV) positive women to colposcopy examination compared to the current standard triage methods of cytology and HPV16\u002F18 genotyping.\n\nThere are two main hypotheses:\n\n1. Urine self-sampling for HPV testing is an acceptable cervical screening option for women in the community.\n2. Combining urine HPV testing with DNA methylation will increase the detection rate of high-grade lesions without increasing the colposcopy referral rate.\n\nTarget participants:\n\nWomen between the ages of 26-65 and have a history of sexual activity, not have a history of total hysterectomy or cervical cancer, not currently pregnant, not currently under treatment of cervical dysplasia or cervical cancer.\n\nThis is a prospective study and women who are willing to undergo urine self-sampling for HPV test will be recruited from various communities, such as Specialist out-patient clinics of Queen Mary Hospital (Hong Kong), public areas in Queen Mary Hospital (such as lobby of out-patient clinics and corridors), District Health Centres, the Family Planning Association (FPA) clinics, Anticancer Society, Christian Action, Non Government Organizations (NGO), private organizations, and online.\n\nA total of 8,620 women are needed to be recruited to the study: approximately 4,700 onsite and 4,000 online.\n\nStudy procedures:\n\nSelf-collected urine samples from study subjects recruited in various communities will be examined using the INDICAID HPV Urine Test. Women with positive urine HPV results will undergo further testing, including urine DNA methylation and co-testing (cytology and HPV genotyping). They will be triaged to colposcopy when test results show clinical indications. The acceptability and feasibility of the urine test will be assessed by calculating the self-sample uptake rate and analyzing participant-reported questionnaires. The detection rate of high-grade lesions and the colposcopy referral rate will be compared between DNA methylation testing and the current standard methods.",[31],[359,258,360,361,184],"urine HPV test","triage","methylation","2026-03-09",{"date":364,"type":41},"2026-03-12",{"date":287,"type":24},{"date":367,"type":24},"2028-03",{"name":369,"class":48},"The University of Hong Kong",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":18,"sex":56,"minAge":275,"maxAge":21,"enrollmentInfo":377,"targetDuration":4,"studyType":25,"phases":379,"briefSummary":380,"conditions":381,"keywords":385,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":4},"100628469","effect-of-virtual-reality-on-pain-and-anxiety-during-pap-smear-testing-100628469","NCT07462039","Effect of Virtual Reality on Pain and Anxiety During Pap Smear Testing","The Effect of Virtual Reality Transition on Pain and Anxiety Experienced During Pap Smear Testing","Inclusion Criteria:\n\n* Women aged 18-65 years\n* Scheduled for a Pap smear procedure\n* Able to communicate in Turkish\n* Able to understand and complete the study questionnaires\n* Willing to provide written informed consent\n* No visual or hearing impairment preventing the use of a VR headset\n\nExclusion Criteria:\n\n* History of severe motion sickness or vertigo\n* Diagnosed psychiatric disorder affecting anxiety assessment\n* Use of anxiolytic or sedative medication within 24 hours prior to the procedure\n* Presence of acute pelvic pain or active vaginal infection\n* Previous participation in this study\n* Any condition preventing safe use of a VR headset",{"count":378,"type":24},60,[27],"This randomized controlled pretest-posttest experimental study aims to evaluate the effect of virtual reality (VR) on pain and anxiety levels experienced during Pap smear sampling. Although cervical cancer is largely preventable through regular screening, many women avoid Pap smear testing due to anxiety, fear of pain, and discomfort during gynecological examinations. Innovative, non-invasive interventions are needed to improve women's screening experiences and participation rates.\n\nThe study will be conducted in a gynecology outpatient clinic with 60 women aged 18-65 years who meet the inclusion criteria and provide informed consent. Participants will be randomly assigned to either the intervention group (VR headset during the procedure) or the control group (standard care). Women in the intervention group will watch a 360° relaxing nature video during the Pap smear procedure. Data will be collected using a Personal Information Form, the State Anxiety Inventory, and the Visual Analog Scale (VAS). The findings may support integrating VR into clinical practice to enhance patient comfort during screening procedures.",[382,383,31,384],"Nurse's Role","Pain Management","Anxiety",[386,159,387,388,31],"virtual reality","pain","anxiety",{"date":390,"type":41},"2026-03-10",{"date":390,"type":24},{"date":393,"type":24},"2026-05-10",{"name":395,"class":48},"Eastern Mediterranean University",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":56,"minAge":132,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":25,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":422,"leadSponsor":424,"locationsCount":426},"100590550","ameliorated-pap-tests-and-cervical-cancer-screening-participation-100590550","NCT06968871","Ameliorated Pap Tests and Cervical Cancer Screening Participation","Effects of the Ameliorated Pap Test on Cervical Cancer Screening Participation: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 25 or above\n\nExclusion Criteria:\n\n* Ongoing menstruation\n* Pregnancy\n* Incapability of understanding the numeric pain scales\n* Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer)\n* Previous hysterectomy, pelvic surgery, or radiotherapy\n* Active vaginal or uterus infection\n* Analgesic use within 24 hours",{"count":404,"type":24},248,[27],"The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.\n\nThe present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.",[31,408],"Cervical Cancer Screening Methods",[410,34,411,412,413,414,415,416,417],"Cancer screening participation","Multicenter","Multidisciplinary","Pain","Pap smear","Peak-end concept","Preventive medicine","Randomized controlled trial","2026-03-01",{"date":420,"type":41},"2026-03-03",{"date":418,"type":24},{"date":423,"type":24},"2032-12-31",{"name":425,"class":48},"National Taiwan University Hospital",5,{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":435,"targetDuration":437,"studyType":279,"phases":4,"briefSummary":438,"conditions":439,"keywords":443,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":72},"100615312","compliance-to-cervical-cancer-chemoradiation-guidelines-a-multicentric-implementation-audit-and-resource-assessment-initiative-of-national-cancer-grid-of-india-100615312","NCT07290972","Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","NCG-Compliance","The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.\n\nFurthermore any cases referred to the institution for brachytherapy alone will also be included.",{"count":436,"type":24},618,"3 Years","This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+\u002F- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and\u002For concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.\n\nAs a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.\n\nEach of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.\n\nThose centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and \u002For concurrent chemotherapy over a period of 6 months.",[31,440,441,442],"Gynecologic Cancers","Treatment Compliance","Chemoradiotherapy",[34,444,445,446,447,442],"Cancer","Recurrence","Treatment","Compliance","2026-02-03",{"date":450,"type":41},"2026-02-04",{"date":452,"type":41},"2021-02-01",{"date":454,"type":24},"2026-03-31",{"name":456,"class":457},"Tata Memorial Hospital","OTHER_GOV",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":18,"sex":56,"minAge":132,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":25,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":480,"leadSponsor":482,"locationsCount":101},"100596843","accelerating-adoption-of-patient-centered-cervical-cancer-screening-and-treatment-linkage-in-kenya-100596843","NCT07050745","Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya","DADA-LINK","Inclusion Criteria:\n\n\\- Women ages 25-49 years\n\nExclusion Criteria:\n\n* Pregnant women\n* Women ≤6 weeks postpartum\n* Women already confirmed to have cervical cancer","49 Years",{"count":467,"type":24},1980,[27],"This study aims to test the use of a multi-component care strategy (DADA LINK) designed to improve cervical cancer screening and linkage to treatment. The duration of the trial is 12 months, with a 6-month follow-up period to evaluate intervention costs and measure maintenance of the care strategies. Study staff at each clinic will abstract data on cervical cancer screening and triage\u002Ftreatment. Clinics randomized to the intervention arm will have care coordinators who motivate clinic staff to adhere to cervical cancer care guidelines, conduct patient exit surveys to assess intervention fidelity, and support care coordination through use of the mHealth platform (WEMA).",[30,31,144],[185,472,473,474,475,32,35],"screening","m-Health","linkage to treatment","VIA","2026-01-08",{"date":478,"type":41},"2026-01-12",{"date":164,"type":41},{"date":481,"type":24},"2026-12",{"name":483,"class":457},"Kenyatta National Hospital",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":18,"sex":56,"minAge":492,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":25,"phases":496,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":101},"100606138","breast-cancer-related-approach-for-increasing-cervical-cancer-screening-100606138","NCT07171658","Breast Cancer-Related Approach for Increasing Cervical Cancer Screening","Improving Cervical Cancer Screening Coverage Among Underscreened Women Aged 50 to 74 in Switzerland Using HPV Self-sampling Strategies: A Randomized Study - Breast Cancer-Related Approach for Increasing Cervical Cancer Screening","BRAICS","Inclusion Criteria:\n\n* Women receiving Breast Cancer Screening (BCS) invitation letters in the selected five cantons (Geneva, Bern (francophone), Jura, Neuchâtel, and Vaud)\n* Aged 50 to 74 years old\n* Not been screened for cervical cancer in the past three years\n* Speaking one of the 6 languages of the study (French, German, Italian, and in English, Spanish, and Portuguese)\n\nExclusion Criteria:\n\n* Prior cervical cancer diagnosis,\n* Hysterectomy\n* Non consent to participate to the study\n* Incapable of judgment or under tutelage\n* Pregnancy","50 Years","74 Years",{"count":495,"type":24},4500,[27],"The primary objective of this clinical trial is to assess cervical cancer screening participation among under-screened women invited through organized breast cancer screening programs in Switzerland.\n\nThis randomized trial will compare three arms:\n\n1. Intervention group 1: Sensitization to Cervical Cancer (CC) screening Women will receive an awareness letter explaining the importance of cervical cancer screening, the Swiss recommendations and an invitation to schedule an appointment.\n2. Intervention group 2: Home-based Human papillomavirus infection (HPV) self-sampling Women will receive a free-of-charge vaginal self-sampling kit for HPV infection\n3. Observational control group Women selected in the control arm will only be recruited one year following the screening of those in the intervention arm (T0+1), as to not influence Cervical Cancer Screening (CCS) behavior during this period by being reminded of screening recommendations.",[31],[152,500,35,501],"underscreened women","Integrated approach","2025-12-15",{"date":504,"type":41},"2025-12-22",{"date":506,"type":41},"2025-10-07",{"date":122,"type":24},{"name":509,"class":48},"Jessica Di Vincenzo Sormani",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":18,"sex":56,"minAge":20,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":25,"phases":518,"briefSummary":519,"conditions":520,"keywords":523,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":101},"100614110","human-papillomavirus-self-sampling-for-enhancing-cervical-screening-during-the-war-in-ukraine-100614110","NCT07275333","Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine","Inclusion Criteria:\n\n* Female aged 30-60 years\n* Intact uterus (no prior hysterectomy)\n* Eligible for cervical cancer screening according to local guidelines\n* Able to provide informed consent\n* Able to perform self-sampling at home or at a clinic\n\nExclusion Criteria:\n\n* History of total hysterectomy\n* Pregnancy at the time of enrollment\n* Known diagnosis of cervical cancer\n* Inability or unwillingness to provide informed consent\n* Unable to perform self-sampling or comply with study procedures","60 Years",{"count":112,"type":24},[27],"In 2020, a cervical screening center was established in Zaporizhzhia (Ukraine), initiating a pilot project to evaluate the prevalence of HPV among women in Eastern Ukraine. The findings were intended to lay the groundwork for the Ukrainian Ministry of Health in establishing a structured national screening program. However, all efforts were halted due to the nearby armed conflict, situated just 40 kilometers from the border.\n\nThe World Health Organization's goal to eliminate cervical cancer globally has a gap when it comes to managing cancer control during crises like armed conflicts. We propose a demonstration project to assess whether a simpler, yet modern, cervical cancer control strategy (based on using self-sampling for HPV detection) could also be effective for cervical cancer screening in Zaporizhzhia.\n\nWomen aged 30-60 years who have not had a recent negative HPV test will be invited to participate. Participants receive a self-sampling kit from their primary care provider and can return the sample free of charge to the clinic or community volunteers. All samples are analyzed in accredited laboratories in Zaporizhzhia.\n\nHPV-positive women will receive follow-up care according to national guidelines, including referral to gynecologists for additional tests and treatment if needed. HPV-negative women will be reassured and advised on future screening intervals.\n\nThe study also evaluates how well the screening program can be implemented during conflict conditions. This includes measuring women's acceptance of self-sampling, the willingness of providers to adopt the procedures, and whether the screening process is feasible, practical, and sustainable. Additional process evaluation will explore how the program adapts to challenges such as migration, disrupted health services, and safety concerns.\n\nThis project is conducted through collaboration between Zaporizhzhia State Medical and Pharmaceutical University, the Charitable Foundation \"World Against Cancer,\" and Karolinska Institutet in Sweden, which provides quality assurance support for laboratory procedures. The goal is to establish a safe, effective, and sustainable cervical cancer screening model that can be used in conflict-affected regions and similar settings.\n\nThis work is supported by a grant from the Union for International Cancer Control (UICC), as part of the Reimagining Cancer Research in Europe Initiative.",[30,31,521,522],"Human Papillomavirus (HPV) Infection","Cervical Intraepithelial Neoplasia",[524,525,526,527,528,529,530,531,532,533],"hpv self-sampling","hpv testing","cervical cancer prevention","cervical screening","implementation science","war-affected regions","ukraine","High-risk HPV","self-collection","Screening uptake","2025-12-11",{"date":536,"type":41},"2025-12-18",{"date":538,"type":41},"2025-04-01",{"date":540,"type":24},"2026-08-31",{"name":542,"class":48},"Karolinska Institutet",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":56,"minAge":132,"maxAge":465,"enrollmentInfo":551,"targetDuration":4,"studyType":25,"phases":553,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":571},"100606878","optimization-of-cervical-cancer-screening-strategies-among-women-living-with-hiv-effectiveness-and-implementation-of-decentralized-approach-using-a-mobile-team-with-hpv-testing-in-the-western-region-of-cameroon-100606878","NCT07181278","Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of Decentralized Approach Using a Mobile Team With HPV Testing in the Western Region of Cameroon","Optimization of HPV-based Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of Decentralized Approach Using a Mobile Team With HPV Testing in the Western Region of Cameroon","OptiTri_MT","Inclusion Criteria:\n\n* Women\n* HIV infection\n* Age between 25 and 49 years old\n* Receiving or starting ARV treatment\n* Agreeing to participate in the study and having signed the consent\n\nExclusion Criteria:\n\n* Current pregnancy\n* Hysterectomy\n* Treatment of cervical lesions within 12 months\n* Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);\n* Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study\n\nDeferred inclusion if\n\n* menstrual bleeding\n* Postpartum (\\\u003C12 weeks after delivery)\n* Clinical signs of cervical or pelvic infection",{"count":552,"type":24},1180,[27],"Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.\n\nDropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing all the screening and treatment sequences in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts.\n\nDifferent strategies for delivering screening with HPV testing for WLHIV are possible. A first approach (\"centralized approach\") consists of having well equipped reference centres with experienced health workers and referring women to these centers. An alternative consists of having a mobile unit who can bring equipment and health workers and perform the CC screening in the usual places of patient care (\"decentralised\" or mobile team approach). Each of these two approaches has advantages and limitations in terms of coverage, completeness, cost and quality of screening. It is necessary to evaluate them in real life to inform national decision-makers on the best strategy to use in their countries.\n\nThe OptiTri-MU study aims to evaluate and compare the effectiveness of these two strategies for delivering CC screening (\"centralized\" screening versus \"decentralized\" screening). It will also assess the implementation of each strategy and include three sub-studies designed to evaluate :\n\n* the performance of urinary HPV testing.\n* the performance of different methods to identify women requiring a treatment.\n* the risk of post-treatment cervical disease. Design This is a trial in which the intervention (mobile team) will be implemented gradually. All sites starts with the centralized screening strategy. At each period, a new site is ransomly selected and start the the decentralized screening strategy. There will be 6 periods of 10 weeks. The effectiveness of the intervention will be assessed by comparing the outcomes at each site before and after implementation and by comparing the sites with each other. The primary outcome for effectiveness is the screening completeness 120 days after enrollment.\n\nThe study will also assess the implementation of each screening strategy in terms of :\n\n* Success through the measure of fidelity, reach and completeness\n* Identification of adaptation, barriers and facilitating\u002Fleverage factors\n* Perception, feasibility and acceptability of the screening strategies (by patients and health care workers)\n\nOther study objectives include :\n\n* To assess the performance of different methods to identify women requiring a treatment\n* To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples\n* To assess the efficacy of treatment in terms of post-treatment cervical lesions Study population. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.",[31,208],[185,472,208,557,558,559,560,561],"implementation","resource-limited setting","HPV test","decentralization","thermal ablation","2025-11-24",{"date":564,"type":41},"2025-12-02",{"date":566,"type":41},"2025-04-28",{"date":568,"type":24},"2028-08-01",{"name":570,"class":457},"Institut de Recherche pour le Developpement",6,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":56,"minAge":81,"maxAge":21,"enrollmentInfo":579,"targetDuration":4,"studyType":25,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":4},"100610319","development-of-systems-and-education-for-cervical-cancer-prevention-dose-cc-100610319","NCT07226037","Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC)","DOSE-CC","Inclusion Criteria:\n\n* Active patients (defined as having a primary care provider assigned at the clinical site and with an appointment in the past 18 months)\n* Eligible for cervical cancer screening (e.g., has a cervix and not up to date with screening)\n\nExclusion Criteria:\n\n* None",{"count":580,"type":24},80000,[27],"Cervical cancer disproportionately impacts those who have not accessed screening or follow-up. Universal screening has the potential to decrease the overall burden of cervical cancer. However, more than half of the individuals who develop cervical cancer have not been screened in more than 5 years, and 20% did not follow-up after an abnormal result.\n\nTo address this problem, the investigators will adapt and test an intervention to improve cervical screening and follow-up in three different settings: Northeastern US urban inner city (Boston), Southeastern US suburban (Florida), and remote west, rural (Hawaii). Our research group previously developed a successful intervention to improve primary cervical cancer prevention, which will be adapted for cervical cancer screening. The intervention combines education and quality improvement methods using a mechanism called Performance Improvement Continuing Medical Education. This type of intervention is attractive to clinicians because they are able to improve their cancer prevention practices while fulfilling requirements for maintaining board certification.\n\nWhen applied to primary prevention, the intervention improved rates by over 10 percentage points, and gains continued for over 4 years after the intervention concluded. The goal of the proposed research is to adapt the intervention to cervical cancer screening, and to evaluate its effectiveness in improving cervical cancer screening and follow-up after abnormal results.\n\nThe proposed intervention represents an innovative and scalable model for promoting cancer prevention and screening activities by clinicians. Unlike programs that increase administrative burdens on busy clinicians, the proposed intervention allows clinicians to improve cancer prevention practices while simultaneously fulfilling requirements to maintain their board certification and improving the quality of cancer prevention care. It therefore has great potential for widespread dissemination.",[31,30],[577,185,585],"prevention","2025-11-06",{"date":588,"type":41},"2025-11-10",{"date":590,"type":24},"2027-05",{"date":592,"type":24},"2030-01",{"name":594,"class":48},"Boston Medical Center",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":56,"minAge":132,"maxAge":465,"enrollmentInfo":603,"targetDuration":4,"studyType":25,"phases":605,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":101},"100606562","impact-of-a-single-versus-multiple-visits-on-the-cervical-cancer-screening-completeness-feasibility-and-acceptability-among-women-living-with-hiv-in-cameroon-100606562","NCT07177170","Impact of a Single Versus Multiple Visits on the Cervical Cancer Screening Completeness, Feasibility and Acceptability Among Women Living With HIV in Cameroon","Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform","OptiTri_GC","Inclusion Criteria:\n\n* HIV infection\n* receiving antiretroviral therapy\n* living in the department of the study hospital\n\nExclusion Criteria:\n\n* ongoing pregnancy\n* hysterectomy\n* treatment of cervical lesion in the past 12 months\n* Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);\n* Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if\n* menstrual bleeding\n* post-partum (\\\u003C12 weeks after delivery)\n* clinicla signs of cervical or pelvic infection",{"count":604,"type":24},1422,[27],"Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.\n\nDropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing the all screening and treatment sequence in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approaches, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.\n\nThe OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :\n\n* The performance of urinary HPV testing.\n* The performance of different methods to identify women requiring a treatment.\n* The risk of post-treatment cervical disease.\n\nThis study has two periods. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented. The screening overall completeness will be compared between the two periods to assess the differentiated approach effectiveness.\n\nThe study will also assess the implementation of each screening strategy in terms of :\n\n* Success through the measure of fidelity, reach and completeness\n* Identification of adaptation, barriers and facilitating\u002Fleverage factors\n* Perception, feasibility and acceptability of the screening strategies (by patients and health care workers) It will assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies and document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.\n\nOther study objectives include :\n\n* To assess the performance of different methods to identify women requiring a treatment\n* To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples\n* To assess the efficacy of treatment in terms of post-treatment cervical lesions\n\nMethodology. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.",[31,208],[185,472,208,609,557,558,561,559],"differentiated prestation","2025-09-12",{"date":612,"type":41},"2025-09-16",{"date":614,"type":41},"2024-12-12",{"date":590,"type":24},{"name":570,"class":457},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":56,"minAge":275,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":279,"phases":4,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100601660","study-for-prevention-of-cervical-cancer-in-spain-100601660","NCT07113379","Study for Prevention of Cervical Cancer in Spain","REVIVE","Inclusion Criteria:\n\n* Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.\n* Diagnosis established between 2019 and 2024.\n\nExclusion Criteria:\n\n* Patients aged below 18 years at diagnosis.\n* Diagnosis of other cervical cancer histologies (e.g., neuroendocrine tumors, sarcoma, lymphoma).\n* Patents with significant cognitive impairment precluding informed consent for data utilization, where applicable.\n* Patients with incomplete medical records relevant to the study variables.",{"count":250,"type":24},"The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system.\n\nDespite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, 2,259 new cases were diagnosed, that incidence has remained relatively stable in recent years, even decades. Mortality rates have also shown little change, with over 600 deaths annually, totaling nearly 10,000 in the last 15 years.\n\nTo address this, the study plans to include approximately 200 patients diagnosed with cervical cancer in Spain between 2019 and 2024. It is a retrospective, observational, and non-interventional study. Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.",[31,627],"HPV Vaccination","2025-08-07",{"date":630,"type":41},"2025-08-08",{"date":632,"type":24},"2025-10",{"date":634,"type":24},"2026-10",{"name":636,"class":48},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":18,"sex":56,"minAge":275,"maxAge":82,"enrollmentInfo":644,"targetDuration":4,"studyType":25,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":4},"100601540","cervical-cancer-screening-via-self-sampling-100601540","NCT07111819","Cervical Cancer Screening Via Self-sampling","Cervical Cancer Screening Using Self-sampling Approach: Validation of Human Papillomavirus Self-sampling Kits Among Kazakhstani Women","Inclusion Criteria:\n\nEligible participants will be recruited from different outpatient clinics in Kazakhstan located in the different regions (western, eastern, northern, southern, and central parts) of the country, and must meet the following inclusion criteria:\n\n1. age - women 18 years and older;\n2. Intact uterine cervix (no prior total hysterectomy or trachelectomy);\n3. ability to understand and answer questions\u002Fsurveys in Kazakh, Russian or English.\n\nExclusion Criteria:\n\npatients who are\n\n1. younger than 18 years old,\n2. women after total hysterectomy (or other surgery, when the uterine cervix is removed),\n3. pregnant women, and\n4. those who are not able to answer questions in Kazakh, Russian or English will be excluded.",{"count":112,"type":24},[27],"Prevention of cervical cancer is one of the priority areas of the Comprehensive Plan to Combat Cancer in the Republic of Kazakhstan for 2023-2027. High-risk human papillomavirus (HR-HPV) infections cause a wide variety of benign and malignant conditions, including cervical cancer. More than 90% of cervical cancer cases are attributed to HR-HPV infections, with HPV-16 and HPV-18 being reported to cause 70-75% of cases. At the present time, cervical cancer remains the fourth most prevalent cancer among women worldwide. Moreover, the majority of cervical cancer cases (90%) occur in low- and middle-income countries (LMICs), where cervical cancer remains the leading cause of death from cancer. Each year, the number of cervical cancer cases is dynamically increasing globally. Between 2000 and 2020 the absolute number of cervical cancer cases increased from 471 000 to 600 000. In 2020, there were around 350,000 deaths from cervical cancer. Moreover, by 2030 it is estimated that the number of new cervical cancer cases will reach 700 000, and the annual number of deaths will reach 400 000. Therefore, given such a significant annual increase in the number of cases and deaths, the elimination of cervical cancer is a global public health challenge.\n\nThe prevalence of HPV infection in Kazakhstan is high, around 39% among women attending gynecological clinics. Consequently, the cervical cancer incidence in Kazakhstan has increased over the past decade, and cervical cancer is the second leading cancer type among women in the country. Moreover, among Central Asian countries, Kazakhstan has the second-highest incidence rate of cervical cancer. The cervical cancer screening program is covered by the government and utilizes Papanicolaou test (Pap-test) performed by gynecologists in outpatient clinics all over the country. However, the screening coverage was reported to be low, covering only around 46% of the eligible population, and does not reach the demand level of 70% suggested by the World Health Organization (WHO). Furthermore, the national HPV vaccination program has just started in September 2024 and could contribute to the reduction of cervical cancer incidence only in the coming 10 years when the effect of vaccination will have an impact on the decrease of HPV prevalence in the country. A proper cervical cancer screening and screening coverage play a crucial role in cervical cancer prevention and control. Thus, there are many factors found to have an impact on overall screening behavior among Kazakhstani women and the increasing incidence of cervical cancer in the country. However, the current screening practices do not show high efficacy due to low coverage and general low sensitivity of the method used. These factors result in growing cervical cancer incidence in Kazakhstan. Thus, there is an emergent need to improve the screening process by introducing novel and reliable methods of screening. Cervical self-sampling could potentially improve the screening coverage; however, the approach should be validated to prove its effectiveness in the Kazakhstani cultural setting before introduction to the healthcare system.",[31],[649,32,258,35],"Cervical cancer prevention","2025-08-05",{"date":630,"type":41},{"date":653,"type":24},"2025-08-01",{"date":122,"type":24},{"name":656,"class":48},"Nazarbayev University",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":18,"sex":56,"minAge":81,"maxAge":21,"enrollmentInfo":664,"targetDuration":4,"studyType":25,"phases":665,"briefSummary":666,"conditions":667,"keywords":668,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":101},"100533704","comparing-effectiveness-of-physician-assisted-versus-self-assisted-pap-smear-collection-100533704","NCT06229275","Comparing Effectiveness of Physician-assisted Versus Self-assisted Pap Smear Collection","A Study to Evaluate the Effectiveness of the Rover Cervex-Brush Device vs. the Personal Pap Smear Device™ for Collection of Cervical Cells for Detecting Cervical Dysplasia or Neoplasia","Inclusion Criteria:\n\n* Adult women, aged 21-65 years old.\n* Do not have any medical or psychiatric condition affecting the ability to give voluntary informed consent.\n* Be able to read and understand English\n\nExclusion Criteria:\n\n* Participants currently on menses\n* Inability to provide Informed Consent\n* Previous total hysterectomy\n* History of radiation treatment for cervical cancer\n* Pregnancy\n* Medical condition that interferes with conduct of study, in investigator's opinion\n* Evidence of active cervical infection requiring treatment\n* Known bleeding diathesis",{"count":250,"type":24},[27],"This purpose of this research study is to determine the effectiveness of the Personal Pap Smear Device™ to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).",[31],[669],"pap smear collection","2025-07-16",{"date":672,"type":41},"2025-07-20",{"date":674,"type":41},"2024-07-25",{"date":676,"type":24},"2026-03-30",{"name":678,"class":48},"Morehouse School of Medicine"]